To quantify this benefit , we conducted a surgical companion study to CALGB40603 , a randomized phase II , 22 factorial trial of neoadjuvant paclitaxel carboplatin bevacizumab ( B ) followed by doxorubicin plus cyclophosphamide B in stage II-III triple negative breast cancer .